204857-35-2

Upstream product

• 104-86-9 4-chlorobenzylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 42060-30-0 N-(4-chloro-benzyl)-methanesulfonamide 

Downstream Products

• 204857-48-7 (1E,3E)-4-Phenyl-buta-1,3-diene-1-sulfonic acid 4-chloro-benzylamide 
• 220378-20-1 (E)-N-(4-chlorobenzyl)-5-(1-(triphenylmethyl)imidazol-4-yl)-1-pent-2-enesulfonamide 
• 329010-42-6 (1E,3E)-4-Phenyl-buta-1,3-diene-1-sulfonic acid but-3-enyl-(4-chloro-benzyl)-amide 
• 329010-38-0 (1E,3E)-4-Phenyl-buta-1,3-diene-1-sulfonic acid allyl-(4-chloro-benzyl)-amide 
• 329010-41-5 (1E,3E)-Penta-1,3-diene-1-sulfonic acid but-3-enyl-(4-chloro-benzyl)-amide 
• 329010-40-4 (E)-Buta-1,3-diene-1-sulfonic acid but-3-enyl-(4-chloro-benzyl)-amide 
• 329010-37-9 (1E,3E)-Penta-1,3-diene-1-sulfonic acid allyl-(4-chloro-benzyl)-amide 
• 329010-36-8 (E)-Buta-1,3-diene-1-sulfonic acid allyl-(4-chloro-benzyl)-amide 

Relevant academic research and scientific papers

HISTAMINE H3 RECEPTOR LIGANDS

Compounds of formula (I) (and pharmaceutically acceptable salts thereof) are histamine H3 receptor ligands. A in the formula represents (CH2)m, m being from 1 to 3; B is (CH2)n, n being from 1 to 3; x is from 0 to 2; Ris C1 to C10 hydrocarbyl, in which up to 2 carbon atoms may be replaced by O, S or N; and up to 2 hydrogen atoms may be replaced by halogen; Ris H or C1 to C15 hydrocarbyl, in which up to 3 carbon atoms may be replaced by O, S or N, and up to 3 hydrogen atoms may be replaced by halogen; Ris absent when -Y-Z-R2 is attached to W, or is H or C1 to C7 hydrocarbyl when -Y-Z-Ris not attached to W; W is nitrogen; X is -CH2-, -O- or -NR-, Rbeing H or C1 to C3 alkyl; Y replaces a hydrogen atom on any of A, B, W and X, and is C2 to C10 alkylene, in which one non-terminal carbon atom may be replaced by O; and Z is (II), (III), (IV), (V), (VI), or (VII) wherein R, Rand Rare independently H or C1 to C15 hydrocarbyl, in which up to 3 carbon atoms may be replaced by O or N, and up to 3 hydrogen atoms may be replaced by halogen, and Q is H or methyl, or Q is linked to Ror Rto form a five-membered ring or Q is linked to Rto form a six-membered ring

ω-(Imidazol-4-yl)alkane-1-sulfonamides: a new series of potent histamine H3 receptor antagonists

ω-(1H-Imidazol-4-yl)alkane-1-sulfonamides were prepared and found to be potent histamine H3 receptor antagonists. High receptor affinity and a low difference in the data between the bioassays were achieved with 5-(1H-imidazol-4-yl)pentane-1-sulfonic acid 4-chlorobenzylamide (16). Good in vitro profiles were also obtained for 2-hydroxysulfonamide and vinylsulfonamide analogues. This complements and completes the existing set of imidazole-based sulfonamides and sulfamides. Copyright

1H-4(5)-substituted imidazole derivatives, their preparation and their use as histamine H3 receptor ligands

A compound of the formula wherein R2is an optionally substituted Czto Cgalkylene or alkylene chain; R3is C2to C15optionally substituted hydrocarbyl; X is a bond or —NR4—, wherein

A convenient synthesis of N-alkyl-(E)-1-alkenesulfonamides

A series of vinylsulfonamides 3 has been synthesised through a condensation of N-Boc-methanesulfonamides 1 and aldehydes 2. O-Boc-2-hydroxyalkanesulfonamides were identified as intermediates, arising from N-O transfer of the Boc group. Elimination of OBoc gave the vinylsulfonamides.